Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multicenter, open-label study o evaluate the safety and efficacy of
CART-BCMA in subjects with relapsed/refractory multiple myeloma.